Azitra (AZTR) Depreciation & Amortization (CF) (2022 - 2026)
Azitra (AZTR) reported Depreciation & Amortization (CF) of $37692.0 for Q1 2026, up 10.68% on a YoY basis from $34055.0 in Q1 2025, and up 7.66% quarter-over-quarter from $35010.0 in Q4 2025.
Azitra (AZTR) Depreciation & Amortization (CF) (2022 - 2026) Analysis & Trends
Azitra has reported Depreciation & Amortization (CF) for 5 years, with the latest figure at $37692.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 10.68% year-over-year to $37692.0; the trailing twelve-month figure through Mar 2026 stood at $141706.0 (up 6.71% YoY), and the FY2025 full-year result was $138069.0, up 5.25% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $37692.0, up from $35010.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $37692.0 in Q1 2026, with the low at $30148.0 in Q2 2022.
- Historically, Depreciation & Amortization (CF) has averaged $33201.1 across 5 years, with a median of $32620.5 in 2023.
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) slipped 0.46% — and 2026, when it gained 10.68%.
- Azitra's Depreciation & Amortization (CF) stood at $32370.0 in 2022, then dropped by 0.33% to $32263.0 in 2023, then gained by 3.02% to $33238.0 in 2024, then increased by 5.33% to $35010.0 in 2025, then rose by 7.66% to $37692.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $37692.0 (Q1 2026), $35010.0 (Q4 2025), and $34766.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Azitra | 20,900.00 | 20,900.00 | - | 37,692.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37,692.00 |
| Mar 31, 2026 | 37,692.00 |
| Dec 31, 2025 | 35,010.00 |
| Dec 31, 2025 | 35,010.00 |
| Sep 30, 2025 | 34,766.00 |
| Sep 30, 2025 | 34,766.00 |
| Jun 30, 2025 | 34,238.00 |
| Jun 30, 2025 | 34,238.00 |
| Mar 31, 2025 | 34,055.00 |
| Mar 31, 2025 | 34,055.00 |
| Dec 31, 2024 | 33,238.00 |
| Dec 31, 2024 | 33,238.00 |
| Sep 30, 2024 | 32,997.00 |
| Sep 30, 2024 | 32,997.00 |
| Jun 30, 2024 | 32,507.00 |
| Jun 30, 2024 | 32,507.00 |
| Mar 31, 2024 | 32,446.00 |
| Mar 31, 2024 | 32,446.00 |
| Dec 31, 2023 | 32,263.00 |
| Dec 31, 2023 | 32,263.00 |